genOway S.A.
ALGEN.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.18 | 0.61 | -0.38 |
| FCF Yield | 0.00% | 0.00% | 7.02% | 0.00% |
| EV / EBITDA | 32.36 | 84.78 | 122.77 | 7.64 |
| Quality | ||||
| ROIC | 0.00% | -16.89% | 3.41% | 4.24% |
| Gross Margin | 0.00% | 68.86% | 64.54% | 179.21% |
| Cash Conversion Ratio | – | – | 4.60 | – |
| Growth | ||||
| Revenue 3-Year CAGR | 23.23% | 22.73% | 17.24% | 11.57% |
| Free Cash Flow Growth | 0.00% | -100.00% | 0.00% | 100.00% |
| Safety | ||||
| Net Debt / EBITDA | 32.36 | 1.41 | 4.63 | 0.52 |
| Interest Coverage | 1.75 | -27.33 | -12.39 | -38.69 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 5.94 | 6.14 | -8.64 |
| Cash Conversion Cycle | 67.55 | 30.57 | 9.57 | 119.89 |